BACKGROUND: Obesity is associated with an increased risk of developing hyperinsulinemia, dyslipidemia, hypertension, premature atherosclerosis, and coronary artery disease in the future.
AIM: This study is designed to assess the relationship between serum adiponectin, asymmetric dimethylarginine (ADMA), and lipid profile among Egyptian overweight and obese children.
METHODS: This cross sectional case control study included 40 selected pre-pubertal overweight and obese children, 24 girls (60%) and 16 boys (40%) aged between 5 to 13 years (8.85 ± 2.7 years), from new cases attending the National nutrition institute clinic during 2013. Forty apparently healthy children of matched age and sex were recruited as a control group.
RESULTS: Obese group showed highly significant higher levels of serum ADMA, triglycerides, and total cholesterol compared with healthy controls (P < 0.000 in all). However, serum adiponectin levels were highly significant lower in obese children compared to healthy controls (P < 0.000). Serum ADMA showed significant positive correlations with height, serum total cholesterol and serum triglycerides levels and significant negative correlation with the body mass index and weight for age z score. Serum adiponectin showed significant negative correlations with BMI, weight, and weight for age z score and significant positive correlation with serum triglycerides. By linear regression analysis; serum adiponectin, and serum triglycerides levels were significant predictors of high serum ADMA level (p =0.045 and 0.015 respectively). BMI, weight, height and serum triglycerides were significant predictors of low serum adiponectin levels (p = 0.005, 0.022, 0.026 and 0.015 respectively).
CONCLUSIONS: Our results revealed that ADMA, Adiponectin and lipid profile can be considered as predictive biomarkers in prediction and prevention of atherosclerotic risk in the future among overweight and obese Egyptian children.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007; 132: 2087-2102.
2. Biro FM, Wien M. Childhood obesity and adult morbidities. Am J Clin Nutr. 2010; 91:1499-1505.
3. Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev Suppl. 2004; 5: 4-104.
4. Hamdy O, Ledbury S, Mullooly C. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care. 2003; 26: 2119-25.
5. Díez JJ, Iglesias P. The role of the adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003; 148 (3): 293-300.
6. Adamska, AN, Kowalska IM, Otiose E, Górska M, Strączkowski M. Relationships between serum adiponectin and soluble TNF-a receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetologica. 2012; 49(1):17-27.
7. Hara K, Yamauchi T, Kadowaki T. Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep. 2005;5(2):136-40.
8. Ukkola O, Santaniemi M. Adiponectin as link between excess adiposity and associated comorbidities? J Mol Med. 2005; 80 (11): 696-702.
9. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk, Arteriosclerosis, Thrombosis, and Vascular Biology. 2003; 23(2): 168-175.
10. Gennaro CV, Bianchi M, Pascale V. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit. 2009; 15(4): 91-101.
11. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2004; 20: 2032-2037.
12. Gruber HJ, Mayer C, Meinitzer A. Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp Clin Endocrinol Diabetes. 2008; 116: 520-24.
13. World Health Organization, Expert Committee: Physical status: The use and interpretation of anthropometry. In WHO technical report series 854. Geneva: Report of a WHO Expert Committee, 1995.
15. Nijveldt, RJ, Teerlink TB, Van der Hoven MP, Siroen DJ, Kuik JA, Rauwerda PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr. 2003;22: 23-30.
16. Fassati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982; 28: 2077-2080.
17. Richmond W. Preparation and properties of a cholesterol oxidase from Nocrdia spand its application to the enzymatic assay of cholesterol in serum. Clin Chem. 1973; 19: 1350-1356.
18. Bonvecchio A, Safdie M, Monterrubio EA, Gust T, Villalpando S, Rivera JA. Overweight and obesity trends in Mexican children 2 to 18 years of age from 1988 to 2006. Salud Pub Mex. 2009; 51(Suppl 4):S586-S594.
19. Codrington C, Sarri K, Kafatos A. Stakeholder appraisal of policy options for tackling obesity in Greece. Obes Rev. 2007; 8 (Suppl 2):63-73.
20. Hassan NE, EL-Ashry HH, Awad AH, El-Masry SA, Youssef M M, Sallam M M, Anwar M. Adiponectin in obese children and its association with blood pressure and anthropometric markers. Medical Research Journal. 2011; 10 (1): 1-4.
21. El Derwi D, El Sherbiny N, Atta AH. Exploring Fayoum (Upper Egypt) preparatory school students’ and teachers’ attitude towards obesity as health risk. J Public Health Epidemiol. 2011; 3: 401-406.
22. Shaheen FM, Hathout M, Tawfik AA. National survey of obesity in Egypt. Cairo: Egypt National Nutrition Institute, 2004.
23. Fatih K, Mehmet T, Sami E, Coskun K, Unlu A, Turgut K, Akif V, Kenan D, Selim A. Serum asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci Monit. 2010; 16(11): 536-539.
24. Teplan V, Schuck O, Racek J. Asymmetric dimethylarginine in obesity after renal transplantation. J Ren Nutr. 2008; 18: 513-20.
25. Kanazawa S, Notsu Y, Yamaguchi H, Nabika T, Sugimoto T. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Clinical Endocrinology. 2011; 74(4): 467-472.
26. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine as a marker for cardiovascular disease and mortality. Clinical Chemistry and Laboratory Medicine. 2005;43(10):1124-1129.
27. Sahinarslan A, Cengel A, Biberoglu G, Hasanoglu A, Turkoglu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis. 2006; 17: 605-609.
28. Hasanoğlu A, Okur I, Oren AC, Biberoğlu G, Oktar S, Eminoğlu FT, Tümer L. The levels of asymmetric dimethylarginine, homocysteine and carotid intima-media thickness in hypercholesterolemic children. Turk J Pediatr. 2011;53(5):522-7.
29. Su SC, Pei D, Hsieh CH, Hsiao FC, Wu CZ, Hung YJ. Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol. 2011;48(2):113-9.
30. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86: 1930-1935.
31. Wagner A, Simon C, Oujaa M, Platat C, Schweitzer B, Arveiler D. Adiponectin is associated with lipid profile and insulin sensitivity in French adolescents. Diabetes Metab. 2008; 34: 465-471.
32. Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88: 3626-3631.
33. Klünder M, Flores-Huerta S, García-Macedo R, Jesús PR, Miguel CZ. Adiponectin in eutrophic and obese children as a biomarker to predict metabolic syndrome and each of its components. BMC Public Health. 2013; 13:88-96.
34. Arnaiz P, Acevedo M, Barja S, Aglony M, Guzmán B, Cassis B. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Int J Cardiol. 2010; 138: 138-144.
35. Schoppen S, Riestra P, García-Anguita A, López-Simón L, Cano B, de Oya I. Leptin and adiponectin levels in pubertal children: relationship with anthropometric variables and body composition. Clin Chem Lab Med. 2010; 48: 707-711.
36. Ogawa Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Uchiyama M. Usefulness of Serum Adiponectin Level as a Diagnostic Marker of Metabolic Syndrome in Obese Japanese Children. Hypertension Research. 2005; 28: 51-57.
37. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res. 2003; 11: 072-1079.
38. Cambuli VM, Musiu MC, Incani M, Paderi M, Serpe R, Marras V. Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. J Clin Endocrinol Metab. 2008; 93: 3051-3057.